Basketball Legend Pau Gasol joins Idoven in a new investment round. Read more here.
For pharmaceutical companies, Idoven develops ECG-based disease biomarkers towards patient identification, risk stratification and prognosis.
Our AI technology is also applied to streamline and standardise cardiovascular safety monitoring during clinical trials and post-market approval.
For example, patients with Heart Failure have scheduled in-person follow-ups 2 to 4 times per year in which a 10 second ECG is performed. However, the onset of the signs of decompensated heart failure can occur 2 to 3 weeks before a major cardiovascular event, and if detected early, hospital re-admission and its associated costs can be avoided.
Remote and continuous monitoring solutions are primarily used to obtain a diagnosis, such as a 30-day heart monitor. These devices are bulky and involve wires, impede on daily activities, and are only used by patients for a short period of time.
Many effective medications come with cardiotoxicity or adverse events, particularly common in oncology. Adverse effects can range from uncomfortable symptoms to sudden cardiac death. Monitoring and managing the cardiovascular safety of treatments requires separate and time-consuming visits to a cardiologist.
Idoven delivers patient identification and monitoring solutions that offer an easy and consistent way to pick up early signs of cardiac abnormalities, triggered by cardiovascular diseases, cancer, kidney disease and other disease areas. The solution consists of:
Idoven's AI algorithms to analyse ECGs in a rapid manner, to evaluate treatment effect and subclinical changes in cardiac electrical signals
A 3rd party wearable ECG (e.g., smartwatch) or mobile ECG device (e.g., holter, patch) customised to the use case
A customizable app (or preferred mode) where non-cardiologist and cardiologist clinicians can visualise patient ECGs and results
Clinicians can monitor patients in between in-person visits, receive alerts of troublesome trends in real time and intervene before patients need to be hospitalized.
For pharmaceutical companies, Idoven develops ECG-based disease biomarkers towards patient identification, risk stratification and prognosis.
Our AI technology is also applied to streamline and standardise cardiovascular safety monitoring during clinical trials and post-market approval.
For example, patients with Heart Failure have scheduled in-person follow-ups 2 to 4 times per year in which a 10 second ECG is performed. However, the onset of the signs of decompensated heart failure can occur 2 to 3 weeks before a major cardiovascular event, and if detected early, hospital re-admission and its associated costs can be avoided.
Remote and continuous monitoring solutions are primarily used to obtain a diagnosis, such as a 30-day heart monitor. These devices are bulky and involve wires, impede on daily activities, and are only used by patients for a short period of time.
Many effective medications come with cardiotoxicity or adverse events, particularly common in oncology. Adverse effects can range from uncomfortable symptoms to sudden cardiac death. Monitoring and managing the cardiovascular safety of treatments requires separate and time-consuming visits to a cardiologist.
Idoven delivers patient identification and monitoring solutions that offer an easy and consistent way to pick up early signs of cardiac abnormalities, triggered by cardiovascular diseases, cancer, kidney disease and other disease areas. The solution consists of:
Idoven's AI algorithms to analyse ECGs in a rapid manner, to evaluate treatment effect and subclinical changes in cardiac electrical signals
A 3rd party wearable ECG (e.g., smartwatch) or mobile ECG device (e.g., holter, patch) customised to the use case
A customizable app (or preferred mode) where non-cardiologist and cardiologist clinicians can visualise patient ECGs and results
Clinicians can monitor patients in between in-person visits, receive alerts of troublesome trends in real time and intervene before patients need to be hospitalized.
For pharmaceutical companies, Idoven develops ECG-based disease biomarkers towards patient identification, risk stratification and prognosis.
Our AI technology is also applied to streamline and standardise cardiovascular safety monitoring during clinical trials and post-market approval.
For example, patients with Heart Failure have scheduled in-person follow-ups 2 to 4 times per year in which a 10 second ECG is performed. However, the onset of the signs of decompensated heart failure can occur 2 to 3 weeks before a major cardiovascular event, and if detected early, hospital re-admission and its associated costs can be avoided.
Remote and continuous monitoring solutions are primarily used to obtain a diagnosis, such as a 30-day heart monitor. These devices are bulky and involve wires, impede on daily activities, and are only used by patients for a short period of time.
Many effective medications come with cardiotoxicity or adverse events, particularly common in oncology. Adverse effects can range from uncomfortable symptoms to sudden cardiac death. Monitoring and managing the cardiovascular safety of treatments requires separate and time-consuming visits to a cardiologist.
Idoven delivers patient identification and monitoring solutions that offer an easy and consistent way to pick up early signs of cardiac abnormalities, triggered by cardiovascular diseases, cancer, kidney disease and other disease areas. The solution consists of:
Idoven's AI algorithms to analyse ECGs in a rapid manner, to evaluate treatment effect and subclinical changes in cardiac electrical signals
A 3rd party wearable ECG (e.g., smartwatch) or mobile ECG device (e.g., holter, patch) customised to the use case
A customizable app (or preferred mode) where non-cardiologist and cardiologist clinicians can visualise patient ECGs and results
Clinicians can monitor patients in between in-person visits, receive alerts of troublesome trends in real time and intervene before patients need to be hospitalized.
For pharmaceutical companies, Idoven develops ECG-based disease biomarkers towards patient identification, risk stratification and prognosis.
Our AI technology is also applied to streamline and standardise cardiovascular safety monitoring during clinical trials and post-market approval.¹
For example, patients with Heart Failure have scheduled in-person follow-ups 2 to 4 times per year in which a 10 second ECG is performed. However, the onset of the signs of decompensated heart failure can occur 2 to 3 weeks before a major cardiovascular event, and if detected early, hospital re-admission and its associated costs can be avoided.
Remote and continuous monitoring solutions are primarily used to obtain a diagnosis, such as a 30-day heart monitor. These devices are bulky and involve wires, impede on daily activities, and are only used by patients for a short period of time.
Many effective medications come with cardiotoxicity or adverse events, particularly common in oncology. Adverse effects can range from uncomfortable symptoms to sudden cardiac death. Monitoring and managing the cardiovascular safety of treatments requires separate and time-consuming visits to a cardiologist.
Idoven delivers patient identification and monitoring solutions that offer an easy and consistent way to pick up early signs of cardiac abnormalities, triggered by cardiovascular diseases, cancer, kidney disease and other disease areas. The solution consists of:
Idoven's AI algorithms to analyse ECGs in a rapid manner, to evaluate treatment effect and subclinical changes in cardiac electrical signals
A 3rd party wearable ECG (e.g., smartwatch) or mobile ECG device (e.g., holter, patch) customised to the use case
A customizable app (or preferred mode) where non-cardiologist and cardiologist clinicians can visualise patient ECGs and results
Clinicians can monitor patients in between in-person visits, receive alerts of troublesome trends in real time and intervene before patients need to be hospitalized.
.png)
.png)
.png)
